×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
LON:FAB

Fusion Antibodies (FAB) Share Forecast, Price & News

GBX 55.50
0.00 (0.00%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
53
55.50
50-Day Range
53
69.50
52-Week Range
53
149.25
Volume
7,461 shs
Average Volume
24,281 shs
Market Capitalization
£14.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive FAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Fusion Antibodies logo

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
55
Year Founded
N/A

Sales & Book Value

Annual Sales
£4.70 million
Cash Flow
GBX 7.12 per share
Book Value
GBX 16.40 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£14.44 million
Optionable
Not Optionable

Company Calendar

Today
5/27/2022
Next Earnings (Estimated)
8/08/2022

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Fusion Antibodies (LON:FAB) Frequently Asked Questions

When is Fusion Antibodies' next earnings date?

Fusion Antibodies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Fusion Antibodies
.

Who are Fusion Antibodies' key executives?
Fusion Antibodies' management team includes the following people:
  • Mr. James Fair, CFO, Company Sec. & Director (Age 56, Pay $125k)
  • Dr. Richard John Buick Ph.D., Chief Scientific Officer & Director (Age 46, Pay $131k)
  • Dr. Paul Gerard Kerr, Consultant (Age 49, Pay $180.38k)
  • Prof. Jim Johnston, Founder
  • Mr. Hugh Morgan Ph.D., Director of Operations
What other stocks do shareholders of Fusion Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include D4t4 Solutions (D4T4), Aminex (AEX), Eurasia Mining (EUA), Dril-Quip (DRQ), 4D pharma (DDDD), ABM Industries (ABM), Card Factory (CARD), Blockchain Worldwide (BLOC), ATTRAQT Group (ATQT) and (APHA).

What is Fusion Antibodies' stock symbol?

Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB."

How do I buy shares of Fusion Antibodies?

Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Fusion Antibodies' stock price today?

One share of FAB stock can currently be purchased for approximately GBX 55.50.

How much money does Fusion Antibodies make?

Fusion Antibodies has a market capitalization of £14.44 million and generates £4.70 million in revenue each year.

How many employees does Fusion Antibodies have?

Fusion Antibodies employs 55 workers across the globe.

What is Fusion Antibodies' official website?

The official website for Fusion Antibodies is fusionantibodies.com.

How can I contact Fusion Antibodies?

Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.